BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19453414)

  • 21. Molecular signature of high yield (growth) influenza a virus reassortants prepared as candidate vaccine seeds.
    Ramanunninair M; Le J; Onodera S; Fulvini AA; Pokorny BA; Silverman J; Devis R; Arroyo JM; He Y; Boyne A; Bera J; Halpin R; Hine E; Spiro DJ; Bucher D
    PLoS One; 2013; 8(6):e65955. PubMed ID: 23776579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment of Vero cell RNA polymerase I-driven reverse genetics for Influenza A virus and its application for pandemic (H1N1) 2009 influenza virus vaccine production.
    Song MS; Baek YH; Pascua PNQ; Kwon HI; Park SJ; Kim EH; Lim GJ; Choi YK
    J Gen Virol; 2013 Jun; 94(Pt 6):1230-1235. PubMed ID: 23486669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
    Jadhao SJ; Achenbach J; Swayne DE; Donis R; Cox N; Matsuoka Y
    Vaccine; 2008 Mar; 26(14):1742-50. PubMed ID: 18336962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets.
    Forrest HL; Khalenkov AM; Govorkova EA; Kim JK; Del Giudice G; Webster RG
    Vaccine; 2009 Jun; 27(31):4187-95. PubMed ID: 19406182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of the H5N1 influenza virus vaccine strain to decrease the pathogenicity in chicken embryos.
    Isoda N; Sakoda Y; Okamatsu M; Tsuda Y; Kida H
    Arch Virol; 2011 Apr; 156(4):557-63. PubMed ID: 21203786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets.
    Chen Z; Kim L; Subbarao K; Jin H
    Vaccine; 2012 Mar; 30(15):2516-22. PubMed ID: 22330124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A two dose immunization with an inactivated reassortant H5N2 virus protects chickens against lethal challenge with homologous 2.3.2.1 clade and heterologous 2.2 clade highly pathogenic avian influenza H5N1 viruses.
    Bhat S; Sood R; Shukla S; Khandia R; Pateriya AK; Kumar N; Singh VK; Kalaiyarasu S; Kumar M; Bhatia S
    Vet Microbiol; 2018 Apr; 217():149-157. PubMed ID: 29615248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1.
    Zhou F; Zhou J; Ma L; Song S; Zhang X; Li W; Jiang S; Wang Y; Liao G
    Biochem Biophys Res Commun; 2012 May; 421(4):850-4. PubMed ID: 22554519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials).
    Rudenko L; Desheva J; Korovkin S; Mironov A; Rekstin A; Grigorieva E; Donina S; Gambaryan A; Katlinsky A
    Influenza Other Respir Viruses; 2008 Nov; 2(6):203-9. PubMed ID: 19453396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.
    van der Velden MV; Geisberger A; Dvorak T; Portsmouth D; Fritz R; Crowe BA; Herr W; Distler E; Wagner EM; Zeitlinger M; Sauermann R; Stephan C; Ehrlich HJ; Barrett PN; Aichinger G
    Clin Vaccine Immunol; 2014 Jun; 21(6):867-76. PubMed ID: 24739978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Broadening the H5N3 Vaccine Immunogenicity against H5N1 Virus by Modification of Neutralizing Epitopes.
    Rajesh Kumar S; Chelvaretnam S; Tan Y; Prabakaran M
    Viruses; 2017 Dec; 10(1):. PubMed ID: 29295514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective efficacy of a high-growth reassortant H1N1 influenza virus vaccine against the European Avian-like H1N1 swine influenza virus in mice and pigs.
    Ruan BY; Wen F; Gong XQ; Liu XM; Wang Q; Yu LX; Wang SY; Zhang P; Yang HM; Shan TL; Zheng H; Zhou YJ; Tong W; Gao F; Tong GZ; Yu H
    Vet Microbiol; 2018 Aug; 222():75-84. PubMed ID: 30080677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of single dose of a bivalent vaccine containing inactivated Newcastle disease virus and reassortant highly pathogenic avian influenza H5N1 virus against lethal HPAI and NDV infection in chickens.
    Lee DH; Park JK; Kwon JH; Yuk SS; Erdene-Ochir TO; Jang YH; Seong BL; Lee JB; Park SY; Choi IS; Song CS
    PLoS One; 2013; 8(3):e58186. PubMed ID: 23469269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness.
    Tseng YF; Hu AY; Huang ML; Yeh WZ; Weng TC; Chen YS; Chong P; Lee MS
    PLoS One; 2011; 6(10):e24057. PubMed ID: 22022351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.
    Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
    Vaccine; 2017 Jul; 35(33):4177-4183. PubMed ID: 28668565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective efficacy of intranasal cold-adapted influenza A/New Caledonia/20/99 (H1N1) vaccines comprised of egg- or cell culture-derived reassortants.
    Palker T; Kiseleva I; Johnston K; Su Q; Toner T; Szymkowiak C; Kwan WS; Rubin B; Petrukhin L; Wlochowski J; Monteiro J; Kraiouchkine N; DiStefano D; Rudenko L; Shaw A; Youil R
    Virus Res; 2004 Oct; 105(2):183-94. PubMed ID: 15351492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural Reassortants of Potentially Zoonotic Avian Influenza Viruses H5N1 and H9N2 from Egypt Display Distinct Pathogenic Phenotypes in Experimentally Infected Chickens and Ferrets.
    Naguib MM; Ulrich R; Kasbohm E; Eng CLP; Hoffmann D; Grund C; Beer M; Harder TC
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza.
    Shoji Y; Chichester JA; Jones M; Manceva SD; Damon E; Mett V; Musiychuk K; Bi H; Farrance C; Shamloul M; Kushnir N; Sharma S; Yusibov V
    Hum Vaccin; 2011; 7 Suppl():41-50. PubMed ID: 21266846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.